Abstract
The dioxin/aryl hydrocarbon receptor functions as a ligand-activated transcription factor regulating transcription of a battery of genes encoding primarily drug-metabolizing enzymes. Expression of a constitutively active mutant of the aryl hydrocarbon receptor (CA-AhR) in transgenic mice results in development of stomach tumours, correlating with increased mortality. We have used suppression subtractive hybridization techniques followed by macroarray analysis to elucidate which genes are differentially expressed during this process. In the glandular stomach of CA-AhR mice, we observed decreased mRNA expression of osteopontin (OPN), a noncollagenous protein of bone matrix that is also involved in several important functions including regulation of cytokine production, macrophage accumulation, cell motility and adhesion. Downregulated expression of OPN during tumour development was confirmed by RT–PCR and RNA blot analysis. Immunohistochemical analysis showed that this decrease was confined to the corpus region, correlating with the restricted localization of the tumours. Decreased OPN mRNA expression was also observed in other organs of CA-AhR mice. Taken together, these results show that OPN is negatively regulated by the dioxin receptor, and that downregulation of its expression correlates with development of stomach tumours in mice expressing a constitutively active mutant of dioxin receptor.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- CYP1A1:
-
cytochrome P450 1A1
- CA-AhR:
-
constitutively active aryl hydrocarbon receptor
- ARNT:
-
arylhydrocarbon receptor nuclear translocator
- NMO1:
-
NAD[P]H:menadione oxidoreductase 1
- OPN:
-
osteopontin
- GAPDH:
-
glyceraldehyde-3-phosphate dehydrogenase
- XRE:
-
xenobiotic response element
- SSH:
-
suppression subtractive hybridization
References
Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D and Yeatman TJ . (2002). J. Natl. Cancer Inst., 94, 513–521.
Andersson P, McGuire J, Rubio C, Gradin K, Whitelaw ML, Pettersson S, Hanberg A and Poellinger L . (2002). Proc. Natl. Acad. Sci. USA, 99, 9990–9995.
Andersson P, Ridderstad A, McGuire J, Pettersson S, Poellinger L and Hanberg A . (2003). Biochem. Biophys. Res. Commun., 302, 336–341.
Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ and Cantor H . (2000). Science, 287, 860–864.
Baumgarth N, Herman OC, Jager GC, Brown L and Herzenberg LA . (1999). Proc. Natl. Acad. Sci. USA, 96, 2250–2255.
Baumgarth N, Herman OC, Jager GC, Brown LE, Herzenberg LA and Chen J . (2000). J. Exp. Med., 192, 271–280.
Bidder M, Shao JS, Charlton-Kachigian N, Loewy AP, Semenkovich CF and Towler DA . (2002). J. Biol. Chem., 277, 44485–44496.
Boes M, Prodeus AP, Schmidt T, Carroll MC and Chen J . (1998). J. Exp. Med., 188, 2381–2386.
Brown LF, Berse B, Van de Water L, Papadopoulos-Sergiou A, Perruzzi CA, Manseau EJ, Dvorak HF and Senger DR . (1992). Mol. Biol. Cell, 3, 1169–1180.
Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF and Senger DR . (1994). Am. J. Pathol., 145, 610–623.
Church GM and Gilbert W . (1984). Proc. Natl. Acad. Sci. USA, 81, 1991–1995.
Craig AM and Denhardt DT . (1991). Gene, 100, 163–171.
Crawford HC, Matrisian LM and Liaw L . (1998). Cancer Res., 58, 5206–5215.
Denhardt DT, Giachelli CM and Rittling SR . (2001a). Annu. Rev. Pharmacol. Toxicol., 41, 723–749.
Denhardt DT, Mistretta D, Chambers AF, Krishna S, Porter JF, Raghuram S and Rittling SR . (2003). Clin. Exp. Metastasis, 20, 77–84.
Denhardt DT and Noda M . (1998). J. Cell. Biochem. Suppl., 30-31, 92–102.
Denhardt DT, Noda M, O'Regan AW, Pavlin D and Berman JS . (2001b). J. Clin. Invest., 107, 1055–1061.
Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SS, Kimura S, Nebert DW, Rudikoff S, Ward JM and Gonzalez FJ . (1995). Science, 268, 722–726.
Fernandez-Salguero PM, Ward JM, Sundberg JP and Gonzalez FJ . (1997). Vet. Pathol., 34, 605–614.
Frueh FW, Hayashibara KC, Brown PO and Whitlock Jr JP . (2001). Toxicol. Lett., 122, 189–203.
Furger KA, Menon RK, Tuckl AB, Bramwelll VH and Chambers AF . (2001). Curr. Mol. Med., 1, 621–632.
Gillesby BE, Stanostefano M, Porter W, Safe S, Wu ZF and Zacharewski TR . (1997). Biochemistry, 36, 6080–6089.
Gu YZ, Hogenesch JB and Bradfield CA . (2000). Annu. Rev. Pharmacol. Toxicol., 40, 519–561.
Iizuka J, Katagiri Y, Tada N, Murakami M, Ikeda T, Sato M, Hirokawa K, Okada S, Hatano M, Tokuhisa T and Uede T . (1998). Lab. Invest., 78, 1523–1533.
Kleman MI, Poellinger L and Gustafsson J̊ . (1994). J. Biol. Chem., 269, 5137–5144.
Kolluri SK, Balduf C, Hofmann M and Göttlicher M . (2001). Cancer Res., 61, 8534–8539.
Kolluri SK, Weiss C, Koff A and Göttlicher M . (1999). Genes Dev., 13, 1742–1753.
Kurachi M, Hashimoto S, Obata A, Nagai S, Nagahata T, Inadera H, Sone H, Tohyama C, Kaneko S, Kobayashi K and Matsushima K . (2002). Biochem. Biophys. Res. Commun., 292, 368–377.
Lahvis GP, Lindell SL, Thomas RS, McCuskey RS, Murphy C, Glover E, Bentz M, Southard J and Bradfield CA . (2000). Proc. Natl. Acad. Sci. USA, 97, 10442–10447.
McGuire J, Okamoto K, Whitelaw ML, Tanaka H and Poellinger L . (2001). J. Biol. Chem., 276, 41841–41849.
Mimura J, Ema M, Sogawa K and Fujii-Kuriyama Y . (1999). Genes Dev., 13, 20–25.
Mimura J, Yamashita K, Nakamura K, Morita M, Takagi TN, Nakao K, Ema M, Sogawa K, Yasuda M, Katsuki M and Fujii-Kuriyama Y . (1997). Genes Cells, 2, 645–654.
Miyazaki Y, Setoguchi M, Yoshida S, Higuchi Y, Akizuki S and Yamamoto S . (1990). J. Biol. Chem., 265, 14432–14438.
Morimoto I, Sasaki Y, Ishida S, Imai K and Tokino T . (2002). Genes Chromosomes Cancer, 33, 270–278.
Nemir M, Bhattacharyya D, Li X, Singh K, Mukherjee AB and Mukherjee BB . (2000). J. Biol. Chem., 275, 969–976.
Ochsenbein AF, Fehr T, Lutz C, Suter M, Brombacher F, Hengartner H and Zinkernagel RM . (1999). Science, 286, 2156–2159.
Ohbayashi T, Oikawa K, Iwata R, Kameta A, Evine K, Isobe T, Matsuda Y, Mimura J, Fujii-Kuriyama Y, Kuroda M and Mukai K . (2001). FEBS Lett., 508, 341–344.
Oikawa K, Ohbayashi T, Mimura J, Fujii-Kuriyama Y, Teshima S, Rokutan K, Mukai K and Kuroda M . (2002). Biochem. Biophys. Res. Commun., 290, 984–987.
Paciorkowski N, Porte P, Shultz LD and Rajan TV . (2000). J. Exp. Med., 191, 731–736.
Pohjanvirta R and Tuomisto J . (1994). Pharmacol. Rev., 46, 483–549.
Puga A, Maier A and Medvedovic M . (2000). Biochem. Pharmacol., 60, 1129–1142.
Qu H, Brown LF, Dvorak HF and Dvorak AM . (1997). J. Histochem. Cytochem., 45, 21–33.
Renault MA, Jalvy S, Belloc I, Pasquet S, Sena S, Olive M, Desgranges C and Gadeau AP . (2003). Circ. Res., 93, 674–681.
Rittling SR and Chambers AF . (2004). Br. J. Cancer, 90, 1877–1881.
Rivera SP, Saarikoski ST and Hankinson O . (2002). Mol. Pharmacol., 61, 255–259.
Sambrook J, Fritsch EF and Maniatis T . (1989). Molecular Cloning: A Laboratory Manual 2 edn. Cold Spring Harbour Laboratory Press: Cold Spring Harbour, NY.
Schmidt JV, Su GH, Reddy JK, Simon MC and Bradfield CA . (1996). Proc. Natl. Acad. Sci. USA, 93, 6731–6736.
Suh J, Jeon YJ, Kim HM, Kang JS, Kaminski NE and Yang KH . (2002). Toxicol. Appl. Pharmacol., 181, 116–123.
Svensson C and Lundberg K . (2001). Mol. Pharmacol., 60, 135–142.
Thomas RS, Rank DR, Penn SG, Zastrow GM, Hayes KR, Pande K, Glover E, Silander T, Craven MW, Reddy JK, Jovanovich SB and Bradfield CA . (2001). Mol. Pharmacol., 60, 1189–1194.
Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T and Tahara E . (1998). Int. J. Cancer, 79, 127–132.
von Stein OD . (2001). Methods Mol. Biol., 175, 263–278.
Yumoto K, Ishijima M, Rittling SR, Tsuji K, Tsuchiya Y, Kon S, Nifuji A, Uede T, Denhardt DT and Noda M . (2002). Proc. Natl. Acad. Sci. USA, 99, 4556–4561.
Acknowledgements
We would like to thank Professor Ann F Chambers, University of Western Ontario and London Regional Cancer Centre, Canada, for providing us with osteopontin cDNA. This work was supported by the Swedish Cancer Society, The Foundation for Strategic Environmental Research, The Swedish Environmental Protection Agency (the ReproSafe programme) and The Swedish Council for Environment Agricultural Sciences and Spatial Planning.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kuznetsov, N., Andersson, P., Gradin, K. et al. The dioxin/aryl hydrocarbon receptor mediates downregulation of osteopontin gene expression in a mouse model of gastric tumourigenesis. Oncogene 24, 3216–3222 (2005). https://doi.org/10.1038/sj.onc.1208529
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208529
Keywords
This article is cited by
-
Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target
Archives of Toxicology (2017)